

JÃ©rÃ©me Avouac

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3574938/publications.pdf>

Version: 2024-02-01

182
papers

8,847
citations

34105

52
h-index

51608

86
g-index

195
all docs

195
docs citations

195
times ranked

8793
citing authors

#	ARTICLE	IF	CITATIONS
1	Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. <i>Lancet Rheumatology</i> , The, 2022, 4, e8-e11.	3.9	29
2	Revue des rÃ©cents essais randomisÃ©s dans la sclÃ©rodermie systÃ©mique. <i>Revue Du Rhumatisme (Edition) Tj</i> 0.0	0.0	0
3	Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients. <i>Rheumatology</i> , 2022, 61, S1163-S1168.	1.9	18
4	Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study. <i>Rheumatology</i> , 2022, 61, 2755-2769.	1.9	17
5	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. <i>Arthritis Research and Therapy</i> , 2022, 24, 13.	3.5	6
6	The role of antifibrotic therapies in the treatment of systemic sclerosisâ€associated interstitial lung disease. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2110666.	2.7	0
7	Erosive arthritis autoantibodies in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151947.	3.4	7
8	Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151951.	3.4	5
9	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022, 61, 4384-4396.	1.9	10
10	Driving Role of Interleukinâ€2â€Related Regulatory <scp>CD4</scp> + T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 1387-1398.	5.6	13
11	Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection. <i>Rheumatology</i> , 2022, , .	1.9	1
12	Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses. <i>RMD Open</i> , 2022, 8, e002308.	3.8	11
13	Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e37-e37.	0.9	71
14	DonnÃ©es rÃ©centes sur la prise en charge clinique de la sclÃ©rodermie systÃ©mique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 24-31.	0.0	0
15	Influence of inflammatory and non-inflammatory rheumatic disorders on the clinical and biological profile of type-2 diabetes. <i>Rheumatology</i> , 2021, 60, 3598-3606.	1.9	5
16	Ethnic influence on the phenotype of French patients with systemic sclerosis. <i>Joint Bone Spine</i> , 2021, 88, 105081.	1.6	13
17	To apply the recent EULAR recommendations, more knowledge on adherence patterns to medication and to physical activity is needed. <i>Joint Bone Spine</i> , 2021, 88, 105137.	1.6	3
18	Rapidly Progressive Systemic Sclerosisâ€associated Interstitial Lung Disease After Intravesical Bacillus Calmette-GuÃ©rin Therapy for Early-stage Bladder Cancer. <i>Journal of Rheumatology</i> , 2021, 48, 1348-1349.	2.0	2

#	ARTICLE	IF	CITATIONS
19	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
20	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e419-e426.	3.9	211
21	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	2.7	37
22	Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1579-1588.	5.6	15
23	Cellules CAR-TÃ©: extension aux maladies auto-immunes en rhumatologie. <i>Revue Du Rhumatisme (Edition) Tj ETQq1</i> 1, 0.784314 rgBT / 0, 0	0.0	0
24	Editorial: Key Players in Systemic Sclerosis: The Immune System and Beyond. <i>Frontiers in Immunology</i> , 2021, 12, 770419.	4.8	3
25	Is There a Place for Chimeric Antigen ReceptorÃ©T Cells in the Treatment of Chronic Autoimmune RheumaticÃ©Diseases?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1954-1965.	5.6	28
26	An update on recent randomized clinical trials in systemic sclerosis. <i>Joint Bone Spine</i> , 2021, 88, 105184.	1.6	2
27	Influence of perceived barriers and facilitators for physical activity on physical activity levels in patients with rheumatoid arthritis or spondyloarthritis: a cross-sectional study of 150 patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 915.	1.9	10
28	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	3.9	42
29	Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
30	Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 163-164.	0.8	9
31	Systemic sclerosis: Recent insight in clinical management. <i>Joint Bone Spine</i> , 2020, 87, 293-299.	1.6	31
32	Estrogens Counteract the Profibrotic Effects of TGF-Î² and their Inhibition Exacerbates Experimental Dermal Fibrosis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 593-601.e7.	0.7	15
33	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	5.8	43
34	Systemic sclerosis pathogenesis: contribution of recent advances in genetics. <i>Current Opinion in Rheumatology</i> , 2020, 32, 505-514.	4.3	30
35	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1065-1074.	3.0	5
36	Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. <i>PLoS ONE</i> , 2020, 15, e0232978.	2.5	26

#	ARTICLE	IF	CITATIONS
37	Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 891-900.	0.9	13
38	Disease Activity Score in 28 Joints Using GGT Permits a Dual Evaluation of Joint Activity and Cardiovascular Risk. <i>Journal of Rheumatology</i> , 2020, 47, 1738-1745.	2.0	4
39	Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 480-491.	3.4	41
40	Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1339-1347.	3.4	12
41	Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1449-1456.	3.4	29
42	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	8.4	31
43	Anticoagulation in Autoimmune Rheumatic Diseases. , 2020, , 159-179.		1
44	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSSciper inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.9	31
45	How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?â€”MTX in the Treat-to-Target Strategy. <i>Journal of Clinical Medicine</i> , 2019, 8, 515.	2.4	54
46	SAT0038â€¦SEMAPHORINS: FROM ANGIOGENESIS TO INFLAMMATION IN RHEUMATOID ARTHRITIS. , 2019, , .		0
47	SAT0254â€¦VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
48	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1681-1685.	0.9	13
49	Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 149-159.	1.7	5
50	Performance of Candidate Serum Biomarkers for Systemic Sclerosisâ€”Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 972-982.	5.6	101
51	¹⁸ F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 577-578.	0.9	17
52	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.9	12
53	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	1.9	60
54	Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 741-748.	3.4	63

#	ARTICLE	IF	CITATIONS
55	Prevalence and Disease-specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. <i>Arthritis Care and Research</i> , 2018, 70, 1218-1227.	3.4	7
56	Targeting Costimulatory Pathways in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 2998.	4.8	30
57	Regulatory T Cells in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 2356.	4.8	67
58	T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 197.	3.5	40
59	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 58, 254-259.	1.9	11
60	Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0203607.	2.5	2
61	Soluble CD163 as a Potential Biomarker in Systemic Sclerosis. <i>Disease Markers</i> , 2018, 2018, 1-5.	1.3	25
62	From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 82-87.	0.8	5
63	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.9	132
64	Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 86-94.	3.4	71
65	Targeting synovial neoangiogenesis in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2017, 16, 594-601.	5.8	80
66	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
67	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
68	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. <i>Rheumatology</i> , 2017, 56, 1874-1883.	1.9	10
69	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2209-2221.	5.6	17
70	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1931-1940.	0.9	67
71	Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 537-543.	3.4	25
72	Tendons, Joints, and Bone. , 2017, , 507-523.		0

#	ARTICLE	IF	CITATIONS
73	Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FIRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 35-42.	0.8	12
74	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
75	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
76	Reports from the 2015 American College of Rheumatology Congress. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 16-20.	1.7	0
77	Updates on animal models of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 266-276.	1.7	14
78	Intestin des connectivites et vascularites. <i>Revue Du Rhumatisme Monographies</i> , 2016, 83, 249-255.	0.0	1
79	Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acroosteolysis in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 366-373.	3.4	40
80	Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2142-2149.	0.9	56
81	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1009-1015.	0.9	112
82	Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2175-2183.	0.9	68
83	Small, medium but not large arteries are involved in digital ulcers associated with systemic sclerosis. <i>Joint Bone Spine</i> , 2016, 83, 444-447.	1.6	10
84	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. <i>International Journal of Cardiology</i> , 2016, 223, 385-389.	1.7	16
85	OX40L blockade protects against inflammation-driven fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3901-10.	7.1	50
86	Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease. <i>Arthritis Care and Research</i> , 2016, 68, 1021-1027.	3.4	28
87	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.9	111
88	Tribbles homologue 3 stimulates canonical TGF- β 2 signalling to regulate fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 609-616.	0.9	38
89	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 115-123.	3.4	84
90	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 149, 1482-1493.	0.8	63

#	ARTICLE	IF	CITATIONS
91	Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1541-1549.	0.9	38
92	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 439-445.	3.4	23
93	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 43-48.	0.8	1
94	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 181-185.	0.8	20
95	Identification of NF- κ B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 71.	3.5	41
96	Systemic sclerosis: Recent insights. <i>Joint Bone Spine</i> , 2015, 82, 148-153.	1.6	54
97	Outcome of Patients with Systemic Sclerosis in the Intensive Care Unit. <i>Journal of Rheumatology</i> , 2015, 42, 1406-1412.	2.0	19
98	Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models. <i>Journal of Inflammation</i> , 2015, 12, 9.	3.4	14
99	Cardiac Biomarkers in Systemic Sclerosis: Contribution of High-Sensitivity Cardiac Troponin in Addition to N-Terminal Pro-Brain Natriuretic Peptide. <i>Arthritis Care and Research</i> , 2015, 67, 1022-1030.	3.4	54
100	All-cause Mortality Associated with TNF- α Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Medicine</i> , 2015, 128, 1367-1373.e1.	1.5	8
101	Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 1801-1807.	2.0	46
102	Trabecular Bone Score in Female Patients with Systemic Sclerosis: Comparison with Rheumatoid Arthritis and Influence of Glucocorticoid Exposure. <i>Journal of Rheumatology</i> , 2015, 42, 228-235.	2.0	42
103	S100A4 amplifies TGF- β 2-induced fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1748-1755.	0.9	52
104	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 99-105.	2.0	73
105	Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. <i>Arthritis Research and Therapy</i> , 2014, 16, R157.	3.5	68
106	The Nuclear Receptor Constitutive Androstane Receptor/NR113 Enhances the Profibrotic Effects of Transforming Growth Factor β 2 and Contributes to the Development of Experimental Dermal Fibrosis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3140-3150.	5.6	13
107	Flare of calcinosis despite rituximab therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, e5-e6.	3.4	18
108	Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. <i>Journal of Rheumatology</i> , 2014, 41, 2395-2402.	2.0	63

#	ARTICLE	IF	CITATIONS
109	Inflammation and Disease Activity are Associated with High Circulating Cardiac Markers in Rheumatoid Arthritis Independently of Traditional Cardiovascular Risk Factors. <i>Journal of Rheumatology</i> , 2014, 41, 248-255.	2.0	56
110	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 191-197.	0.9	41
111	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF- β 2 signalling to prevent fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1215-1222.	0.9	78
112	Systemic Sclerosis-related Acute Myocardial Infarction: Definition. <i>American Journal of Medicine</i> , 2014, 127, e37.	1.5	0
113	Different patterns of skin manifestations associated with parvovirus B19 primary infection in adults. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 62-69.	1.2	46
114	Association study of CRP gene in systemic sclerosis in European Caucasian population. <i>Rheumatology International</i> , 2014, 34, 389-392.	3.0	2
115	Mouse Model of Experimental Dermal Fibrosis: The Bleomycin-Induced Dermal Fibrosis. <i>Methods in Molecular Biology</i> , 2014, 1142, 91-98.	0.9	22
116	Targeted immunotherapies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 165-72.	0.8	7
117	Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2013, 15, R55.	3.5	62
118	Systemic sclerosis at the crossroad of polyautoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 1052-1057.	5.8	62
119	Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts. <i>Journal of Rheumatology</i> , 2013, 40, 1706-1711.	2.0	23
120	Conseils d''utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisés par la Haute Autorité de santé française. <i>Revue Du Rhumatisme (Edition Française)</i> , 2013, 80, 459-466.	0.0	6
121	Recommendations for using TNF α antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. <i>Joint Bone Spine</i> , 2013, 80, 574-581.	1.6	48
122	Experimental models of dermal fibrosis and systemic sclerosis. <i>Joint Bone Spine</i> , 2013, 80, 23-28.	1.6	17
123	Performance of Skin Ultrasound to Measure Skin Involvement in Different Animal Models of Systemic Sclerosis. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 845-852.	1.5	5
124	Hand and Wrist Involvement in Systemic Sclerosis: US Features. <i>Radiology</i> , 2013, 269, 824-830.	7.3	57
125	Brief Report: A Regulatory Variant in <i>CCR6</i> Is Associated With Susceptibility to Antitopoisomerase-Positive Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 3202-3208.	6.7	26
126	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1089-1098.	0.9	35

#	ARTICLE	IF	CITATIONS
127	Reply. Arthritis Care and Research, 2013, 65, 1016-1016.	3.4	0
128	Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Annals of the Rheumatic Diseases, 2013, 72, 1217-1220.	0.9	160
129	Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. Arthritis Research and Therapy, 2013, 15, R165.	3.5	18
130	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 737-745.	0.9	53
131	Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 394-399.	0.9	53
132	Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology, 2012, 51, 1017-1026.	1.9	345
133	Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 997-1003.	2.0	35
134	Articular involvement in systemic sclerosis. Rheumatology, 2012, 51, 1347-1356.	1.9	76
135	Increased risk of osteoporosis and fracture in women with systemic sclerosis: A comparative study with rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 1871-1878.	3.4	68
136	Familial Autoimmunity in Systemic Sclerosis â€” Results of a French-based Case-Control Family Study. Journal of Rheumatology, 2012, 39, 532-538.	2.0	24
137	Tendons, Joints, and Bone. , 2012, , 531-545.		0
138	Recommandations pour le traitement de lâ€™arthrose du genou: sont-elles applicables? Kinesithérapie, 2012, 12, 28-39.	0.1	0
139	Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care and Research, 2012, 64, 1244-1249.	3.4	53
140	Inhibition of activator protein 1 signaling abrogates transforming growth factor ð€“mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis and Rheumatism, 2012, 64, 1642-1652.	6.7	81
141	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 2724-2733.	6.7	133
142	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Annals of the Rheumatic Diseases, 2011, 70, 1178-1182.	0.9	30
143	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research and Therapy, 2011, 13, 114.	3.5	8
144	Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Annals of the Rheumatic Diseases, 2011, 70, 476-481.	0.9	330

#	ARTICLE	IF	CITATIONS
145	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 800-809.	6.7	73
146	C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2091-2096.	6.7	45
147	Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. <i>Arthritis and Rheumatism</i> , 2011, 63, 2790-2796.	6.7	53
148	Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells. <i>Arthritis and Rheumatism</i> , 2011, 63, 3552-3562.	6.7	26
149	Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2011, 38, 2419-2427.	2.0	4
150	Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. <i>Rheumatology</i> , 2011, 50, 1494-1504.	1.9	21
151	The transcription factor JunD mediates transforming growth factor β -induced fibroblast activation and fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1320-1326.	0.9	59
152	Association Study of <i>ITGAM</i> , <i>ITGAX</i> , and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. <i>Journal of Rheumatology</i> , 2011, 38, 1033-1038.	2.0	22
153	Genome-Wide Scan Identifies <i>TNIP1</i> , <i>PSORS1C1</i> , and <i>RHOB</i> as Novel Risk Loci for Systemic Sclerosis. <i>PLoS Genetics</i> , 2011, 7, e1002091.	3.5	205
154	Independent replication establishes the <i>CD247</i> gene as a genetic systemic sclerosis susceptibility factor. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1695-1696.	0.9	46
155	Management recommendations for knee osteoarthritis: How usable are they?. <i>Joint Bone Spine</i> , 2010, 77, 458-465.	1.6	38
156	High DNA Oxidative Damage in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 2540-2547.	2.0	64
157	Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies. <i>Journal of Rheumatology</i> , 2010, 37, 2290-2298.	2.0	259
158	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1360-1363.	0.9	34
159	Dermal tissue and cellular expression of fibrillin-1 in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2010, 49, 657-661.	1.9	10
160	Efficacy of joint lavage in knee osteoarthritis: meta-analysis of randomized controlled studies. <i>Rheumatology</i> , 2010, 49, 334-340.	1.9	25
161	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. <i>Journal of Rheumatology</i> , 2010, 37, 1488-1501.	2.0	161
162	Association of Metalloproteinase Gene Polymorphisms with Systemic Sclerosis in the European Caucasian Population. <i>Journal of Rheumatology</i> , 2010, 37, 599-602.	2.0	10

#	ARTICLE	IF	CITATIONS
163	Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. <i>Journal of Rheumatology</i> , 2010, 37, 105-115.	2.0	37
164	Associated Autoimmune Diseases in Systemic Sclerosis Define a Subset of Patients with Milder Disease: Results from 2 Large Cohorts of European Caucasian Patients. <i>Journal of Rheumatology</i> , 2010, 37, 608-614.	2.0	73
165	Phenotype-Haplotype Correlation of <i>IRF5</i> in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity. <i>Journal of Rheumatology</i> , 2010, 37, 987-992.	2.0	54
166	Association Study of Serotonin Transporter Gene (SLC6A4) in Systemic Sclerosis in European Caucasian Populations. <i>Journal of Rheumatology</i> , 2010, 37, 1164-1167.	2.0	10
167	Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity. <i>Arthritis Research and Therapy</i> , 2010, 12, R27.	3.5	40
168	Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009, 36, 2356-2361.	2.0	43
169	Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 1481-1485.	2.0	57
170	Severe Refractory Rheumatoid Arthritis Successfully Treated with Combination Rituximab and Anti-Tumor Necrosis Factor-Î±-Blocking Agents. <i>Journal of Rheumatology</i> , 2009, 36, 2125.2-2126.	2.0	9
171	Angiotensin-Converting Enzyme Gene Does Not Contribute to Genetic Susceptibility to Systemic Sclerosis in European Caucasians. <i>Journal of Rheumatology</i> , 2009, 36, 337-340.	2.0	15
172	SclÃ©rodermie systÃ©mique: Ã©tat des lieux en 2008. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2008, 75, 918-924.	0.0	0
173	Cardiac involvement in systemic sclerosis assessed by tissueâ€doppler echocardiography during routine care: A controlled study of 100 consecutive patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 1803-1809.	6.7	171
174	Endothelial progenitor cells and rheumatic disorders. <i>Joint Bone Spine</i> , 2008, 75, 131-137.	1.6	42
175	Systemic sclerosis: an update in 2008. <i>Joint Bone Spine</i> , 2008, 75, 650-655.	1.6	54
176	Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. <i>Journal of Rheumatology</i> , 2008, 35, 643-9.	2.0	15
177	New therapeutic strategies in the management of systemic sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 607-615.	1.8	49
178	Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders. <i>Current Rheumatology Reviews</i> , 2007, 3, 95-101.	0.8	0
179	Association polyarthrite rhumatoÃ©de etÃ©cirrhose biliaire primitive. <i>Revue Du Rhumatisme (Edition)</i> Tj ETQq1 1 0.784314 rgBT /Overlo	0.0	1
180	Association between rheumatoid arthritis and primary biliary cirrhosis. <i>Joint Bone Spine</i> , 2007, 74, 279-281.	1.6	27

#	ARTICLE	IF	CITATIONS
181	Arthrose du genou et de la hanche et activité : revue systématique internationale et synthèse (OASIS). Revue Du Rhumatisme (Edition Francaise), 2006, 73, 736-752.	0.0	6
182	Osteoarthritis of the knee and hip and activity: a systematic international review and synthesis (OASIS). Joint Bone Spine, 2006, 73, 442-455.	1.6	216